Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01071538 · ClinicalTrials.gov registry record · Phase 2

Buprenorphine for Late-Life Treatment Resistant Depression

A Phase 2 study of Depression, sponsored by University of Pittsburgh.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target
1
Study location

NCT01071538: Completed Phase 2 study of Depression, sponsored by University of Pittsburgh.

NCT01071538 is a Phase 2 study of Depression that has completed, run by University of Pittsburgh. The registered enrollment target is 15 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01071538, a Phase 2 study of Depression, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.

Primary Outcome

measure of depression severity theoretical scale range 0-60 Lower values represent better outcome

Conditions Studied

Interventions

  • DRUG Buprenorphine

Study Locations (1)

Pennsylvania

  • Western Psychiatric Institute and Clinica, University of Pittsburgh School of Medicine - Pittsburgh

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2010-05
Est. Completion 2012-05
Phase Phase 2
University of Pittsburgh

1,238 total trials

What the finished NCT01071538 record still lists

NCT01071538 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.

NCT01071538 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01071538 about?

NCT01071538 is a clinical study titled "Buprenorphine for Late-Life Treatment Resistant Depression". The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.

What is the current status of trial NCT01071538?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2010-05. Estimated completion is 2012-05.

What conditions does trial NCT01071538 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT01071538?

The interventions under investigation include: Buprenorphine (DRUG).

Who is sponsoring clinical trial NCT01071538?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01071538 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01071538's enrollment target sits among peer trials

15 641st of 679 higher than 33 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01071538, the US trial registry maintained by the National Library of Medicine. NCT01071538 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.